Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

STAT Plus: Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

By ADAM FEUERSTEIN

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis.

READ MORE